Kiniksa Pharmaceuticals (KNSA) to Release Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, April 22nd. Analysts expect the company to announce earnings of $0.06 per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company’s quarterly revenue was up 46.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.35 EPS. On average, analysts expect Kiniksa Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA opened at $20.21 on Monday. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -144.35 and a beta of 0.31. The firm’s 50 day simple moving average is $21.05 and its 200 day simple moving average is $21.45. Kiniksa Pharmaceuticals has a fifty-two week low of $16.87 and a fifty-two week high of $28.15.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KNSA. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush reissued an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $37.17.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 12,000 shares of the firm’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the transaction, the chief operating officer now owns 77,363 shares of the company’s stock, valued at approximately $1,584,394.24. This trade represents a 13.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 36,372 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $510,815.50. This trade represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,766 shares of company stock valued at $2,002,135 in the last quarter. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.